James French Hill
Price Movement Since Trade
How each stock has moved from the trade date to the most recent close.
Suspicious Timing Detected
3 flagsRep. Hill sold $15K-$50K in $CVS on Jan 31, 2025 — 12 days before introducing HR1227 (the Alternatives to PAIN Act), which would lower costs for non-opioid pain treatments, potentially reducing CVS profits from opioid sales.
These flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
Connected Legislative Activity
7 signalsThese bills and contracts share tickers or sectors with this filing's trades.
Ensuring Community Access to Pharmacist Services Act
HR3164 (Ensuring Community Access to Pharmacist Services Act) remains in early committee stage with no funding mechanism. CVS at $82.96 (+6.44% 7-day) and UNH at $366.77 — both moves driven by broader sector momentum, not this specific bill. No measurable near-term revenue impact for any company.
Seniors’ Access to Critical Medications Act of 2025
HR 2484 (Seniors' Access to Critical Medications Act) creates a 2026-2030 Stark law exception allowing physicians to dispense Part D drugs directly. This structurally diverts prescription volume from retail pharmacy chains and PBM networks. CVS and Cigna face direct, measurable revenue erosion; UnitedHealth faces a mixed impact due to its owned physician practices potentially capturing dispensing revenue.
Flexible Savings Arrangements for a Healthy Robust America Act
HR2667 would allow FSA/HRA funds to roll tax-free into HSAs upon HDHP enrollment, expanding the addressable market for HSA administrators and HDHP issuers. The bill is at early stage (referred to Ways and Means, no appropriations). Recent 30-day gains for UNH (+36.1%), HUM (+40.2%) and CVS (+16.4%) are driven by broader sector momentum, not this bill alone. Near-term market impact is limited due to early legislative stage.
Metastatic Breast Cancer Access to Care Act
HR 2048 eliminates the 29-month cumulative waiting period for SSDI and Medicare for metastatic breast cancer patients. The bill is in early legislative stages (referred to Ways and Means), but the identical Senate companion (S3442) increases passage odds. Major health insurers ($UNH, $HUM, $CVS, $CI, $MOH, $CNC) would benefit from accelerated Medicare enrollment, bringing forward premium revenue. Over the past 7 days these tickers have rallied 3.4% to 28.5%, significantly outperforming the broad market, driven in part by sector-wide momentum around Medicare-related legislation.
Alternatives to PAIN Act
The Alternatives to PAIN Act (HR1227) is an early-stage House bill that would eliminate deductibles and lower co-pays for non-opioid pain management drugs under Medicare Part D, effective January 1, 2026. The bill has been referred to two committees with no further action since February 2025. Market impact on Part D sponsors (UNH, CVS, HUM, CI) is currently negligible because the bill is unfunded, in early legislative stages, and faces an uncertain path to enactment.
Preserving Patient Access to Home Infusion Act
The Preserving Patient Access to Home Infusion Act (S.1058) expands Medicare Part B coverage for home infusion therapy, explicitly including pharmacy services and non-pump drugs, and removes the physical presence requirement for per-day payment. This structurally raises addressable revenue for CVS Health's Coram and UnitedHealth Group's Optum infusion businesses. Both stocks show strong momentum — CVS up 15.75% and UNH up 34.54% over 30 days — though the bill is at early legislative stage (referred to committee).
I CAN Act
The I CAN Act (HR1317) structurally lowers healthcare labor costs by expanding APRN scope under Medicare/Medicaid, directly benefiting managed care insurers. Real market data confirms managed-care insurers $CNC (+27.93% 7-day, +63.41% 30-day), $MOH (+10.81% 7-day, +46.26% 30-day), and $HUM (+12.05% 7-day, +39.09% 30-day) are already pricing in this regulatory tailwind. The bill is early-stage but has a companion in the Senate and executive-order tailwinds — pure-play Medicaid/Medicare insurers are the structural winners.
Other Filings by James French Hill
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.